Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial


1Perinatology Research Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development/National Institutes of Health/Department of Health and Human Services, Bethesda, MD and Detroit, MI, USA; 2Department of Obstetrics and Gynecology, Wayne State University/Detroit Medical Center, Hutzel Women’s Hospital, Detroit, MI, USA; 3Center for Molecular Medicine and Genetics, Wayne State University, Detroit, MI, USA; 4Department of Epidemiology, Michigan State University, East Lansing, MI, USA; 5Department of Obstetrics and Gynecology, MedCiti Institute of Medical Services, Andhra Pradesh, India; 6Department of Obstetrics and Gynecology, Government Medical College and Hospital, Maharashtab, India; 7Thomas Jefferson University, Department of Obstetrics and Gynecology, Philadelphia, PA, USA; 8Department of Obstetrics and Gynecology, Cooper University Hospital, Camden, NJ, USA; 9Department of Obstetrics and Gynecology, Shri Ramchandra Medical College and Hospital, Tamil Nadu, India; 10Department of Gynecology, Sheba L.G. Hospital, Gujarat, India; 11Department of Obstetrics and Gynecology, Steve Biko Academic Hospital, Pretoria, South Africa; 12Department of Obstetrics and Gynecology, B.J. Medical College and Sassoun General Hospital, Maharashtra, India; 13Department of Obstetrics and Gynecology and Women’s Health, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, USA; 14Department of Obstetrics and Gynecology of Dnepropetrovsk State Medical Academy, Municipal Establishment ‘City Maternity Hospital # 1’, Dnepropetrovsk, Ukraine; 15Perinatal Diagnostic Center, Central Baptist Hospital, Lexington, KY, USA; 16Department of Obstetrics and Gynecology, University of Kentucky, Lexington, KY, USA; 17Department of Obstetrics and Gynecology of M. Gorky Donetsk National Medical University, Municipal Hospital ‘6th Central City Clinical Hospital’, Donetsk, Ukraine; 181st Department of Obstetrics and Gynecology of Ukrainian State Institute of Human Reproductology of P.L. Shupik National Academy of Postgraduate Education, Pechersk Regional ‘1st Antenatal Out-Patients’ Clinic’, Kiev, Ukraine; 19Winthrop University Hospital, Clinical Trials Center, Mineola, NY, USA; 20Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA, USA; 21University of Pennsylvania Health System, Pennsylvania Hospital, Philadelphia, PA, USA; 22Public Health Services Establishment Minsk ‘1st City Clinic’, Minsk, Republic of Belarus; 23Department of Antenatal Day-Hospital of Municipal Health Care Establishment ‘City Maternity Hospital # 1’, Chernouetz, Ukraine; 24U.O. Ostetricia/Ginecologia, Azienda Ospedaliera di Padova, Padova, Italy; 25Department of Biostatistics, Boston University, School of Public Health, Boston, MA, USA; 26Sage Statistical Solutions, Inc., Elfang, NC, USA; 27Columbia Laboratories, Inc., Livingston, NJ, USA

KEYWORDS: pregnancy; preterm delivery; preterm labor; progestins; progestogens; respiratory distress syndrome; transvaginal ultrasound; uterine cervix; vaginal administration

ABSTRACT

Objectives Women with a sonographic short cervix in the mid-trimester are at increased risk for preterm delivery. This study was undertaken to determine the efficacy and safety of using micronized vaginal progesterone gel to reduce the risk of preterm birth and associated neonatal complications in women with a sonographic short cervix.

Methods This was a multicenter, randomized, double-blind, placebo-controlled trial that enrolled asymptomatic women with a singleton pregnancy and a sonographic short cervix (10–20 mm) at 19 + 0 to 23 + 6 weeks of gestation. Women were allocated randomly to receive vaginal progesterone gel or placebo daily starting from 20 to 23 + 6 weeks until 36 + 6 weeks, rupture of membranes or delivery, whichever occurred first. Randomization sequence was stratified by center and history of a previous preterm birth. The primary endpoint was preterm birth before 33 weeks of gestation. Analysis was by intention to treat.

Correspondence to: Prof. Roberto Romero, Chief, Perinatology Research Branch, Program Director for Perinatal Research and Obstetrics Intramural Division, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, 3990 John R, Detroit, MI 48201, USA (e-mail: romeror@mail.nih.gov)

Accepted: 5 April 2011

Copyright © 2011 ISUOG. Published by John Wiley & Sons, Ltd.
Result**s** Of 465 women randomized, seven were lost to follow-up and 458 (vaginal progesterone gel, n = 235; placebo, n = 223) were included in the analysis. Women allocated to receive vaginal progesterone had a lower rate of preterm birth before 33 weeks than did those allocated to placebo (8.9% (n = 21) vs 16.1% (n = 36); relative risk (RR), 0.55; 95% CI, 0.33–0.92; P = 0.02). The effect remained significant after adjustment for covariables (adjusted RR, 0.52; 95% CI, 0.31–0.91; P = 0.02). Vaginal progesterone was also associated with a significant reduction in the rate of preterm birth before 28 weeks (5.1% vs 10.3%; RR, 0.50; 95% CI, 0.25–0.97; P = 0.04) and 35 weeks (14.5% vs 23.3%; RR, 0.62; 95% CI, 0.42–0.92; P = 0.02), respiratory distress syndrome (3.0% vs 7.6%; RR, 0.39; 95% CI, 0.17–0.92; P = 0.03), any neonatal morbidity or mortality event (7.7% vs 13.5%; RR, 0.57; 95% CI, 0.33–0.99; P = 0.04) and birth weight < 1500 g (6.4% (15/234) vs 13.6% (30/220); RR, 0.47; 95% CI, 0.26–0.85; P = 0.01). There were no differences in the incidence of treatment-related adverse events between the groups.

Conclusions The administration of vaginal progesterone gel to women with a sonographic short cervix in the mid-trimester is associated with a 45% reduction in the rate of preterm birth before 33 weeks of gestation and with improved neonatal outcome. Copyright © 2011 ISUOG. Published by John Wiley & Sons, Ltd.

**INTRODUCTION**

Preterm birth is the leading cause of perinatal morbidity and mortality, and its prevention is an important health-care priority1. In 2005, 12.9 million births worldwide were preterm2. A sonographic short cervix is a powerful predictor of preterm delivery3–25, yet implementation of a screening program of all pregnant women requires the availability of a clinical intervention able to prevent preterm delivery and improve neonatal outcome26. Strategies that have been considered include progesterone administration27, cervical cerclage28–34 and insertion of a pessary35. A randomized clinical trial of vaginal progesterone capsules to prevent preterm delivery (< 34 weeks of gestation) in women with a short cervix (defined as 15 mm or less) reported a 44% reduction in the rate of preterm delivery (19.2% vs 34.4%; relative risk (RR), 0.56; 95% CI, 0.36–0.86), although this was not associated with a significant improvement in maternal outcome27. In addition, secondary analyses of a randomized clinical trial36 of vaginal progesterone in patients with a history of preterm birth showed that progesterone administration was associated with delayed cervical shortening37 as pregnancy progressed, a lower rate of preterm birth, a lower frequency of admission to the neonatal intensive care unit (NICU) and a shorter length of NICU stay38.

This study was undertaken to determine the efficacy and safety of vaginal progesterone gel in reducing the rate of preterm birth before 33 weeks in asymptomatic women with a mid-trimester sonographic short cervix.

**METHODS**

**Study design and participants**

This was a Phase-III, prospective, randomized, placebo-controlled, double-masked, parallel-group, multicenter, international trial. The study was conducted from March 2008 to November 2010 and was approved by the institutional review board of each participating center. Participants provided written informed consent to study coordinators or investigators prior to participation in the trial. Women between 19 + 0 and 23 + 6 weeks of gestation were eligible for screening. During the screening visit, cervical length and gestational age were determined. Women were eligible for the study if they met the following criteria: 1) singleton gestation; 2) gestational age between 19 + 0 and 23 + 6 weeks; 3) transvaginal sonographic cervical length between 10 and 20 mm; and 4) asymptomatic, i.e. without signs or symptoms of preterm labor. Subjects were allocated randomly to receive vaginal progesterone gel or placebo beginning at 20 to 23 + 6 weeks. Gestational age calculation was based on the participant’s reported last menstrual period and fetal biometry39. Exclusion criteria included: 1) planned cerclage; 2) acute cervical dilation; 3) allergic reaction to progesterone; 4) current or recent progestogen treatment within the previous 4 weeks; 5) chronic medical conditions that would interfere with study participation or evaluation of the treatment (e.g. seizures, psychiatric disorders, uncontrolled chronic hypertension, congestive heart failure, chronic renal failure, uncontrolled diabetes mellitus with end-organ dysfunction, active thrombophlebitis or a thromboembolic disorder, history of hormone-associated thrombophlebitis or thromboembolic disorders, active liver dysfunction or disease, known or suspected malignancy of the breast or genital organs); 6) major fetal anomaly or known chromosomal abnormality; 7) uterine anatomic malformation (e.g. bicornuate uterus, septate uterus); 8) vaginal bleeding; or 9) known or suspected clinical chorioamnionitis.

All sonographers involved in sonographic cervical length measurements were required to participate in a training program and to obtain certification before screening patients for the trial. Moreover, the sonographic images of patients enrolled into the trial were reviewed by a central sonologist for quality assurance. An independent data coordinating center was responsible for randomization and data management. Clinical research monitors (Venn Life Sciences (St. Laurent, Quebec, Canada) and PharmOlam International (Houston, TX, USA)) conducted planned, regular site visits at each center, beginning with a site initiation visit and continuing until study completion, to independently assess compliance with the study protocol, timely collection of data, quality control, data completeness and data accuracy, according to International Conference on Harmonization (ICH) and Food and Drug Administration (FDA) Guidelines for Good Clinical Practice40,41. The study included 44 centers in 10 countries.
Randomization and masking

The randomization allocation was 1:1 (vaginal progesterone gel: placebo) and was accomplished using a centralized interactive voice response (IVR) system. Randomization was stratified according to: a) center and b) risk strata (previous preterm birth between 20 and 35 weeks or no previous preterm birth) using a permuted blocks strategy with a block size of four (i.e. two placebo and two vaginal progesterone gel). Contact with the IVR system required the input of subject characteristics and center number, after which the IVR system assigned a treatment for the specific subject based on the strata to which the subject belonged and the next assignment within the randomization block.

Allocation concealment was accomplished in three ways. First, subject drug kits at each study site were numbered independently from the treatment assignments in the randomization blocks to avoid identification of dispensing patterns. Second, the IVR system (upon generating a treatment assignment for a new subject) specified which kit number was to be dispensed to the subject. Third, the study drug packaging, applicators and their contents (vaginal progesterone and placebo) were identical in appearance.

Procedures

All of the drug required throughout the treatment interval for a randomized woman was included in drug kits to be assigned to each patient at each study visit in order to prevent dispensing errors. Prior to dispensing the assigned treatment, demographic, medical and obstetric history and physical examination data were collected from each participant. Treatment was to be initiated between 20 + 0 and 23 + 6 weeks’ gestational age. Women self-administered the study drug once daily in the morning.

Study participants were instructed to return to the study center every 2 weeks. During each visit, subjects were interviewed to determine the occurrence of adverse events, use of concomitant medications and compliance with study drug. Women were asked to return unused study drug from the previous 2 weeks, and determination of compliance was based on the amount of study drug not used.

Study drug was continued until 36 + 6 weeks’ gestational age, rupture of membranes or delivery, whichever occurred first. Both the vaginal progesterone gel (Prochieve® 8%, also known as Crinone® 8%) and placebo were supplied by Columbia Laboratories, Inc. (Livingston, NJ, USA) as a soft, white to off-white gel, in a single-use, one-piece, white disposable polyethylene vaginal applicator with a twist-off top. The progesterone and placebo gels were identical in appearance. Each applicator delivered 1.125 g gel containing 90 mg progesterone or placebo, and was wrapped and sealed in unmarked foil over-wrap. Both the active drug and the placebo were supplied in boxes of 14 applicators and were labeled with a unique kit number. Subjects received a 2-week supply at randomization and at each subsequent visit. They also received a 1-week emergency supply kit at the time of randomization and were resupplied during the treatment period if additional applicators were required before attending the next visit.

Patients who developed preterm labor during the study were treated according to the standard practice of the participating institutions, e.g. admission to the hospital, bed rest, intravenous fluids, tocolytic therapy, steroid administration, if clinically indicated. Administration of the study drug was to be continued during treatment for preterm labor, until delivery (in the absence of preterm rupture of membranes). Maternal and neonatal outcome were recorded throughout study participation and after delivery and discharge using a standardized electronic reporting template.

An emergency cerclage was allowed after randomization if the following criteria were met: 1) 21–26 weeks’ gestational age; 2) cervical dilation > 2 cm; 3) membranes visible; 4) intact membranes; and 5) absence of uterine contractions, clinical chorioamnionitis and significant vaginal bleeding.

The primary outcome of this study was preterm birth before 33 weeks of gestation. The key secondary outcomes were neonatal morbidity, including respiratory distress syndrome (RDS), bronchopulmonary dysplasia, Grade III or IV intraventricular hemorrhage, periventricular leukomalacia, proven sepsis, necrotizing enterocolitis and perinatal mortality (fetal death or neonatal death). Four composite outcome scores were also used to assess perinatal mortality and neonatal morbidity (any event, two 0–4 scales and a 0–6 scale). The definitions for individual outcomes and composite scores are provided in the supplementary material online (Appendix S1). The outcome scores (0–4, 0–6) assigned ordinal values based upon the number of morbid events from 0 to 3 or 0 to 5; the highest number, 4 or 6, was assigned to a mortality event. For one of the 0–4 scores, number of NICU days was also used for assignment of the ordinal value. Other pre-specified secondary outcomes included preterm birth before 28, 35 and 37 weeks of gestation, neonatal length, weight and head circumference at birth and incidence of congenital abnormalities. The frequency of adverse events related to treatment was also assessed (see Appendix S2 online for definition of adverse events). All outcomes were determined and the database was locked prior to the unsealing of the randomization code.

Statistical analysis

We estimated that a sample size of 450 women (225 per treatment group) would have > 90% power (two-tailed alpha level of 0.05) to detect a 55% reduction in the rate of preterm birth before 33 weeks of gestation, from 22% in the placebo group to 9.9% in the vaginal progesterone group.

Analysis of the trial was conducted in three different analysis sets:

1) Intent-to-treat (ITT) analysis set: all patients randomized to either vaginal progesterone gel or placebo;
subjects without a documented delivery date were excluded;
2) Treated patient analysis set: patients who took at least one dose of either placebo or progesterone gel; women who received placebo and had no documented delivery date were considered as if they had delivered at term (37 weeks of gestation); for women who received vaginal progesterone gel and had no documented delivery date, the date of last contact was used as the delivery date;
3) Compliant analysis set: patients who used at least 80% of study medication, did not have a cerclage and were not lost to follow-up.

The primary endpoint of the study, preterm birth before 33 weeks, was analyzed using the Cochran–Mantel–Haenszel (CMH) test. The P-value was assessed at the two-sided significance level of 5%. Analysis of the primary efficacy endpoint was also performed using multivariable logistic regression, in which the following variables were included: treatment group, pooled study site, risk strata, gestational age at first dose, maternal age, cervical length, body mass index (BMI) and race. RR with 95% CI was used as the measure of effect. The CMH test was also used for the analysis of the ordinal composite scores described in Appendix S1 online. For this analysis, a modified ranking procedure (modified ridits) was used to calculate the sum of the expected values for each of the ordinal categories for each of the treatment groups. This ranking procedure is equivalent to non-parametric van Elteren scores. The RR for the primary endpoint was calculated unadjusted, partially adjusted (for pooled study site and risk strata) as well as fully adjusted using multivariable logistic regression. We also calculated the number needed to treat, with 95% CIs for the primary outcome and the most common complication of preterm birth, RDS. All analyses were performed with SAS® 9.2 (SAS Institute Inc., Cary, NC, USA) on a Windows 2003 operating system.

An independent Data and Safety Monitoring Board (DSMB) reviewed unblinded data relevant to safety (not efficacy) after approximately 50% of the subjects had delivered. The observed frequency of adverse events did not exceed that expected or that stated in the informed consent. The DSMB recommended the study continue without modification of the protocol or informed consent. This trial is registered with ClinicalTrials.gov, number NCT00615550.

RESULTS

Of the 32,091 women who underwent sonographic measurement of cervical length between 19 + 0 and 23 + 6 weeks of gestation, 2.3% (733/32,091) were reported to have a cervical length of 10–20 mm. Four hundred and sixty-five women agreed to participate and were randomized, of whom seven were lost to follow-up (vaginal progesterone gel, n = 1; placebo n = 6). Thus, 458 women were included in the ITT analysis set (vaginal progesterone gel, n = 235; placebo, n = 223). Figure 1 shows the participant flow diagram (see Appendix S3 online for further details regarding patient disposition). The trial ended on the delivery date of the last delivered participant. Of the 458 women, 16% (n = 72) had a history of a previous preterm birth between 20 and 35 weeks of gestation.

Baseline maternal characteristics were similar between the placebo and the vaginal progesterone groups (Table 1). There were no differences between the two groups in median duration of treatment (14.3 weeks for vaginal progesterone gel and 13.9 weeks for placebo) or mean study drug administration compliance reported by the investigator (93.3% (SD, ± 13.1%) for vaginal progesterone gel and 94.0% (SD, ± 12.7%) for placebo).

A history of cervical surgery was present in 9.4% (22/235) of patients allocated to receive vaginal progesterone gel and in 12.6% (28/223) of those allocated to the placebo group (P = 0.20). Sixteen women (10 in the vaginal progesterone group and six in the placebo group; P = 0.46) underwent an emergency cervical cerclage after randomization.

Patients allocated to receive vaginal progesterone gel had a significantly lower rate of preterm birth before 33 weeks of gestation compared with those allocated to placebo (8.9% (n = 21) vs 16.1% (n = 36); RR, 0.55; 95% CI, 0.33–0.92; P = 0.02; adjusted (pooled study site and risk strata) RR, 0.54; 95% CI, 0.33–0.89; P = 0.01). Fourteen women with cervical length between 10 and 20 mm would need to be treated with vaginal progesterone gel to prevent one case of preterm birth before 33 weeks of gestation (95% CI, 8–87). Even after
Duration of treatment (weeks) at first dose

Table 1 Baseline and treatment characteristics of 458 asymptomatic women with a singleton pregnancy and sonographic short cervix randomized to receive vaginal progesterone gel or placebo

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Vaginal progesterone (n = 235)</th>
<th>Placebo (n = 223)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>Mean (SD) 13.0 (4.2)</td>
<td>12.5 (4.7)</td>
</tr>
<tr>
<td></td>
<td>Median (range) 14.3 (0–18)</td>
<td>13.9 (0–18)</td>
</tr>
<tr>
<td>Intercquartile range</td>
<td>Mean (SD) 14.3 (1.4)</td>
<td>14.3 (1.4)</td>
</tr>
<tr>
<td></td>
<td>Median (range) 15.0 (9–25)</td>
<td>15.0 (12.9–25)</td>
</tr>
<tr>
<td>GA at first dose</td>
<td>Mean (SD) 17.2 (3.5)</td>
<td>17.5 (3.8)</td>
</tr>
<tr>
<td>of progesterone (weeks)</td>
<td>Median (range) 17.2 (17–25)</td>
<td>17.5 (17–25)</td>
</tr>
<tr>
<td></td>
<td>Interquartile range</td>
<td>(20.4–22.9)</td>
</tr>
<tr>
<td></td>
<td>Mean (SD) 21.9 (1.4)</td>
<td>21.7 (1.4)</td>
</tr>
<tr>
<td></td>
<td>Duration of treatment (weeks)</td>
<td>13.9 (0–18)</td>
</tr>
<tr>
<td></td>
<td>Mean (SD) 12.6 (1.5)</td>
<td>12.5 (4.7)</td>
</tr>
<tr>
<td></td>
<td>Median (range) 16.0 (16–31)</td>
<td>16.0 (16–31)</td>
</tr>
<tr>
<td></td>
<td>Interquartile range</td>
<td>16.0 (16–31)</td>
</tr>
<tr>
<td></td>
<td>Mean (SD) 19.7 (13.1)</td>
<td>19.7 (13.1)</td>
</tr>
<tr>
<td>Compliance (%)</td>
<td>Mean (SD) 99.2 (6–100)</td>
<td>100 (0–100)</td>
</tr>
<tr>
<td></td>
<td>Median (range) 99.2 (6–100)</td>
<td>100 (0–100)</td>
</tr>
<tr>
<td></td>
<td>Intercquartile range</td>
<td>(93.0–100)</td>
</tr>
<tr>
<td></td>
<td>Mean (SD) 93.3 (13.1)</td>
<td>94.0 (12.7)</td>
</tr>
</tbody>
</table>
|                               | *Preterm delivery (PTD) > 20 weeks and < 32 weeks. †Reported compliance was calculated using the following formula: Number of vaginal applicators used since last visit/Number of vaginal applicators that should have been used since last visit) × 100. Every 2 weeks, a percentage of compliance was calculated and the compliance for a specific patient was based on the average of all visits. The definition of compliance was based on the formula and percentage indicated above, and a compliant patient was defined as one with an average of > 80% compliance. GA, gestational age. of preterm birth in women with a prior history of preterm birth between 20 and 35 weeks of gestation did not reach statistical significance (15.8% (6/38) vs 20.6% (7/34); RR, 0.77; 95% CI, 0.29–2.06; P = 0.60).

Vaginal progesterone gel was also associated with a significant reduction in the rate of preterm birth before 35 weeks (14.3% (n = 34) vs 23.3% (n = 52); RR, 0.62; 95% CI, 0.42–0.92; P = 0.02) and before 28 weeks of gestation (5.1% (n = 12) vs 10.3% (n = 23); RR, 0.50; 95% CI, 0.25–0.97; P = 0.04). Figure 2 displays the survival analysis for patients in the entire ITT analysis set (Figure 2a), patients with no prior preterm delivery (Figure 2b) and patients with a prior preterm delivery (Figure 2c). The curves demonstrate a separation between patients allocated to receive vaginal progesterone gel and those in the placebo group. However, there was no difference in the proportion of patients who delivered at < 37 weeks, because the curves converge and overlap at this point. One interpretation of this is that the administration of vaginal progesterone shifted the proportion of patients who would have delivered very preterm to a later gestational age. In addition, vaginal progesterone was associated with a significant reduction in the rate of neonatal birth weight < 1500 g (6.4% (15/234) vs 13.6% (30/220); RR, 0.47; 95% CI, 0.26–0.85; P = 0.01) (Table 2).

In terms of infant outcome, newborns born to women allocated to receive vaginal progesterone gel had a significantly lower frequency of RDS than did those born to women allocated to receive placebo (3.0% (n = 7) vs 7.6% (n = 17); RR, 0.39; 95% CI, 0.17–0.92; P = 0.03). The number needed to treat for benefit was 22 (95% CI, 12–186). This effect remained significant after adjustment for pooled study site and risk strata (RR, 0.40; 95% CI, 0.17–0.94; P = 0.03). The other neonatal outcomes are listed in Table 2. Pre-specified composite scores to assess perinatal mortality/neonatal morbidity were calculated. The rate of any morbidity or mortality was significantly lower in the neonates of subjects allocated to receive vaginal progesterone gel compared with those allocated to receive placebo (7.7% (n = 18) vs 13.5% (n = 30); RR, 0.57; 95% CI, 0.33–0.99; P = 0.04). The composite scores ‘0–4 scale without NICU’ and ‘0–6 scale without NICU’ were also significantly lower in the progesterone gel group compared with the placebo group (P < 0.05 for both comparisons). After adjustment for pooled study site and risk strata, the effect of vaginal progesterone gel on composite perinatal mortality/neonatal morbidity scores ‘any morbidity/mortality event’, ‘0–4 scale without NICU’ and ‘0–6 scale without NICU’ continued to show trends toward improvement (P = 0.054, 0.063 and 0.065, respectively). The frequency of distributions for the perinatal mortality/neonatal morbidity composite scores can be found in Appendix S4 online. Adverse events were comparable between patients who received vaginal progesterone gel and those who received placebo. The rate of adverse events related to study treatment was not significantly different in women who received vaginal progesterone gel compared with

adjustment for pooled study site, risk strata, treatment group, gestational age at first dose, maternal age, cervical length, BMI and race using multivariable logistic regression analysis, the effect of vaginal progesterone gel remained significant for the primary endpoint (adjusted RR, 0.52; 95% CI, 0.31–0.91; P = 0.02). No interaction between treatment and pooled study site was detected (P = 0.2). In women without a history of preterm birth (84% of the population), vaginal progesterone gel administration was associated with a significant reduction in the rate of preterm birth before 33 weeks (7.6% (15/197) vs 15.3% (29/189); RR, 0.50; 95% CI, 0.27–0.90; P = 0.02). However, the reduction in the rate
Vaginal progesterone reduces preterm birth in women with a short cervix

those who received placebo (12.8% (n = 30) vs 10.8% (n = 24); RR, 1.19; 95% CI, 0.72–1.96; P = 0.51); the most frequently reported adverse events related to study treatment occurred in up to 2% of women and included vaginal pruritus, vaginal discharge, vaginal candidiasis and nausea. Furthermore, no fetal or neonatal safety signal was detected for vaginal progesterone gel. Regarding labor and delivery data, there were no meaningful differences in method of delivery. There was one case of a congenital anomaly in the vaginal progesterone group and there were three in the placebo group (RR, 0.32; 95% CI, 0.03–3.02; P = 0.29). Median 1-min and 5-min Apgar scores were comparable between study groups.

**Treated patient analysis set**

Of the 465 women who were randomized, 459 women received at least one dose of study drug (vaginal progesterone gel, n = 235; placebo, n = 224) and represent the ‘treated patient analysis set’. Of these, 16% (n = 71) of the women had a history of a previous preterm birth between 20 and 35 weeks of gestation.

There were no differences between the two groups in the baseline patient characteristics, median duration of treatment (14.3 weeks for vaginal progesterone gel and 13.9 weeks for placebo) or mean study drug administration compliance reported by the investigator (93.3% (SD, ±13.1%) for vaginal progesterone gel and 94.5% (SD, ±10.9%) for placebo). Table 3 displays results of primary and secondary outcomes. After adjustment for study site and risk strata (history of preterm birth), the effect of vaginal progesterone gel remained significant for the reduction in the primary end-point of the rate of preterm birth before 33 weeks of gestation (8.9% (21/235) vs 15.2% (34/224); RR, 0.56; 95% CI, 0.33–0.93; P = 0.02) as well as the rate of RDS (3.0% (7/235) vs 7.1% (16/224); RR, 0.42; 95% CI, 0.18–0.97; P = 0.04). Pre-specified composite scores to assess perinatal mortality/neonatal morbidity were calculated: 0–4 scale without NICU, 0–4 scale with NICU and 0–6 scale without NICU (P = 0.113, 0.103 and 0.113, respectively, for vaginal progesterone gel vs placebo).

Adverse events were comparable between patients who received vaginal progesterone gel and those who received placebo. The rate of adverse events related to study treatment was not significantly different in women who received vaginal progesterone gel compared to those who received placebo (12.8% (30/235) vs 10.7% (24/224); RR, 1.14; 95% CI, 0.72–1.80; P = 0.59); the most frequently reported adverse events related to study treatment occurred in up to 2% of women and included vaginal pruritus, vaginal discharge, vaginal candidiasis and nausea. Furthermore, no fetal or neonatal safety signal was detected for vaginal progesterone gel. Regarding labor and delivery data, there were no differences in the method of delivery. There was one case of a congenital anomaly in the vaginal progesterone gel group and there were three in the placebo group. Median 1-min and 5-min Apgar scores were comparable between the groups. Women allocated to receive vaginal progesterone gel had a lower rate of neonates born weighing <1500 g compared with those

---

**Figure 2** Survival analysis of intent-to-treat analysis set showing proportion of patients remaining undelivered according to treatment allocation: vaginal progesterone (---) vs placebo (- - - - - -). (a) Entire population (patients with and without a prior history of preterm delivery) (vaginal progesterone n = 235, placebo n = 223); (b) patients without a prior history of preterm delivery (vaginal progesterone n = 197, placebo n = 189); (c) patients with a prior history of preterm delivery (vaginal progesterone n = 38, placebo n = 34). P > 0.05 for all comparisons.

in the placebo group (6.4% (15/234) vs 13.3% (29/218); RR, 0.49; 95% CI, 0.27–0.88; \( P = 0.01 \)).

### Compliant analysis set

A pre-specified analysis was conducted in a subgroup (84%, 387/459; vaginal progesterone gel, \( n = 194 \); placebo, \( n = 193 \)) of the treated patient analysis set, excluding those who had < 80% treatment compliance (\( n = 53 \)), those who did not have a documented delivery date (\( n = 4 \)), or who had a cerclage (\( n = 17 \)). One subject had < 80% compliance and a cerclage and one subject had no delivery date and a cerclage.

This compliant analysis set showed for unadjusted analyses that patients allocated to vaginal progesterone gel had a significantly lower frequency of preterm birth than did those allocated to placebo for delivery < 28 weeks of gestation (3.1% (6/194) vs 7.8% (15/193); RR, 0.40; 95% CI, 0.16–1.00; \( P = 0.04 \)), delivery < 33 weeks of gestation (5.7% (11/194) vs 13.0% (25/193); RR, 0.44; 95% CI, 0.22–0.86; \( P = 0.01 \) and delivery < 33 weeks of gestation (10.3% (20/194) vs 20.2% (39/193); RR, 0.51; 95% CI, 0.31–0.84; \( P < 0.01 \)). There was no significant difference in the rate of preterm delivery before 37 weeks of gestation (26.8% (52/194) vs 30.6% (59/193); RR, 0.88; 95% CI, 0.64–1.20; \( P = 0.41 \)). Table 4 displays results of primary outcome and secondary outcomes, RDS and any morbidity/mortality event.

After adjustment for study site and risk strata, the effect of vaginal progesterone gel remained significant for the reduction in the primary endpoint – the rate of preterm birth before 33 weeks of gestation (RR, 0.42; 95% CI, 0.22–0.82; \( P < 0.01 \)) and preterm birth before 35 weeks of gestation (RR, 0.50; 95% CI, 0.31–0.82; \( P < 0.01 \)). Pre-specified composite scores to assess perinatal mortality/neonatal morbidity (0–4 scale without NICU, 0–6 scale with NICU) showed trends towards significance (\( P = 0.058, 0.049 \) and 0.058, respectively).

In summary, there was no evidence of a safety signal, and the evidence for the efficacy of vaginal progesterone gel was demonstrated in a similar manner for both of these additional analysis sets to that demonstrated for the intent-to-treat analysis set.

### DISCUSSION

#### Principal findings of the study

Administration of vaginal progesterone gel to women with a short cervix (10–20 mm) was associated with: 1) a substantial reduction in the rate of preterm delivery < 33 weeks (primary endpoint), < 35 weeks and < 28 weeks of gestation; 2) a significant decrease in the rate of RDS; 3) a similar rate of treatment-related adverse events in patients allocated to progesterone or placebo gel; and 4) no evidence of a ‘safety signal’.

#### Clinical implications of the study

The prevention of preterm birth is a major healthcare priority. The ultimate purpose of interventions designed
Vaginal progesterone reduces preterm birth in women with a short cervix

Table 3

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Vaginal progesterone (n, %)</th>
<th>Placebo (n, %)</th>
<th>Unadjusted RR (95% CI)*</th>
<th>*p</th>
<th>Adjusted RR (95% CI)†</th>
<th>†p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary outcome</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preterm birth &lt; 33 weeks</td>
<td>21 (8.9)</td>
<td>34 (15.2)</td>
<td>0.59 (0.35–0.98)</td>
<td>0.040</td>
<td>0.56 (0.33–0.93)</td>
<td>0.022</td>
</tr>
<tr>
<td>Secondary outcomes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preterm birth &lt; 28 weeks</td>
<td>12 (5.1)</td>
<td>21 (9.4)</td>
<td>0.54 (0.27–1.08)</td>
<td>0.077</td>
<td>0.55 (0.28–1.08)</td>
<td>0.075</td>
</tr>
<tr>
<td>Preterm birth &lt; 35 weeks</td>
<td>34 (14.5)</td>
<td>50 (22.3)</td>
<td>0.65 (0.44–0.96)</td>
<td>0.030</td>
<td>0.61 (0.41–0.90)</td>
<td>0.012</td>
</tr>
<tr>
<td>Preterm birth &lt; 37 weeks</td>
<td>71 (30.2)</td>
<td>74 (33.0)</td>
<td>0.91 (0.70–1.20)</td>
<td>0.516</td>
<td>0.89 (0.68–1.15)</td>
<td>0.377</td>
</tr>
<tr>
<td>RDS</td>
<td>7 (3.0)</td>
<td>16 (7.1)</td>
<td>0.42 (0.17–0.99)</td>
<td>0.041</td>
<td>0.42 (0.18–0.97)</td>
<td>0.036</td>
</tr>
<tr>
<td>BPD</td>
<td>4 (1.7)</td>
<td>5 (2.2)</td>
<td>0.77 (0.21–2.80)</td>
<td>0.683</td>
<td>0.78 (0.21–2.83)</td>
<td>0.701</td>
</tr>
<tr>
<td>Proven sepsis</td>
<td>7 (3.0)</td>
<td>5 (2.2)</td>
<td>1.33 (0.43–4.14)</td>
<td>0.617</td>
<td>1.37 (0.45–4.17)</td>
<td>0.577</td>
</tr>
<tr>
<td>NEC</td>
<td>5 (2.1)</td>
<td>4 (1.8)</td>
<td>1.19 (0.32–4.38)</td>
<td>0.792</td>
<td>1.21 (0.34–4.30)</td>
<td>0.769</td>
</tr>
<tr>
<td>IVH Grade III/IV</td>
<td>0</td>
<td>1 (0.5)</td>
<td>0.32 (0.01–7.76)‡</td>
<td>0.306</td>
<td>0.32 (0.01–7.48)‡</td>
<td>0.307</td>
</tr>
<tr>
<td>PVL</td>
<td>0</td>
<td>0</td>
<td>Not estimable</td>
<td>NA</td>
<td>Not estimable</td>
<td>NA</td>
</tr>
<tr>
<td>Perinatal death</td>
<td>8 (3.4)</td>
<td>10 (4.5)</td>
<td>0.76 (0.31–1.90)</td>
<td>0.559</td>
<td>0.78 (0.31–1.97)</td>
<td>0.596</td>
</tr>
<tr>
<td>Neonatal death</td>
<td>3 (1.3)</td>
<td>5 (2.2)</td>
<td>0.57 (0.14–2.37)</td>
<td>0.435</td>
<td>0.57 (0.14–2.36)</td>
<td>0.436</td>
</tr>
<tr>
<td>Any morbidity/mortality event</td>
<td>18 (7.7)</td>
<td>28 (12.5)</td>
<td>0.61 (0.35–1.08)</td>
<td>0.085</td>
<td>0.62 (0.36–1.08)</td>
<td>0.088</td>
</tr>
<tr>
<td>Birth weight &lt; 1500 g</td>
<td>60/234 (26.6)</td>
<td>67/218 (30.7)</td>
<td>0.83 (0.62–1.12)</td>
<td>0.229</td>
<td>0.83 (0.62–1.11)</td>
<td>0.204</td>
</tr>
<tr>
<td>Birth weight &lt; 1500 g</td>
<td>15/234 (6.4)</td>
<td>29/218 (13.3)</td>
<td>0.48 (0.27–0.87)</td>
<td>0.014</td>
<td>0.49 (0.27–0.88)</td>
<td>0.014</td>
</tr>
</tbody>
</table>

*Unadjusted relative risk (RR) and 95% CI calculated using the Cochran–Mantel–Haenszel (CMH) method; P-value based on CMH test.
†RR and 95% CI calculated using the CMH method adjusted for pooled study site and risk strata; P-value based on CMH test adjusted for pooled study site and risk strata. ‡Based on Logit estimator with continuity correction. BPD, bronchopulmonary dysplasia; GA, gestational age; IVH, intraventricular hemorrhage; NA, not applicable; NEC, necrotizing enterocolitis; PVL, periventricular leukomalacia; RDS, respiratory distress syndrome.

Table 4

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Vaginal progesterone (n, %)</th>
<th>Placebo (n, %)</th>
<th>Unadjusted RR (95% CI)*</th>
<th>*p</th>
<th>Adjusted RR (95% CI)†</th>
<th>†p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary outcome</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preterm birth &lt; 33 weeks</td>
<td>11 (5.7)</td>
<td>25 (13.0)</td>
<td>0.44 (0.22–0.86)</td>
<td>0.014</td>
<td>0.42 (0.22–0.82)</td>
<td>0.009</td>
</tr>
<tr>
<td>Secondary outcomes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preterm birth &lt; 28 weeks</td>
<td>6 (3.1)</td>
<td>15 (7.8)</td>
<td>0.40 (0.16–1.00)</td>
<td>0.043</td>
<td>0.40 (0.16–1.03)</td>
<td>0.048</td>
</tr>
<tr>
<td>Preterm birth &lt; 35 weeks</td>
<td>20 (10.3)</td>
<td>39 (20.2)</td>
<td>0.51 (0.31–0.84)</td>
<td>0.007</td>
<td>0.50 (0.31–0.82)</td>
<td>0.005</td>
</tr>
<tr>
<td>Preterm birth &lt; 37 weeks</td>
<td>52 (26.8)</td>
<td>59 (30.6)</td>
<td>0.88 (0.64–1.20)</td>
<td>0.413</td>
<td>0.85 (0.62–1.17)</td>
<td>0.326</td>
</tr>
<tr>
<td>RDS</td>
<td>7 (3.6)</td>
<td>14 (7.3)</td>
<td>0.50 (0.21–1.21)</td>
<td>0.114</td>
<td>0.48 (0.19–1.17)</td>
<td>0.098</td>
</tr>
<tr>
<td>BPD</td>
<td>3 (1.6)</td>
<td>4 (2.1)</td>
<td>0.75 (0.17–3.29)</td>
<td>0.698</td>
<td>0.85 (0.13–3.90)</td>
<td>0.832</td>
</tr>
<tr>
<td>Proven sepsis</td>
<td>6 (3.1)</td>
<td>5 (2.6)</td>
<td>1.19 (0.37–3.85)</td>
<td>0.767</td>
<td>1.18 (0.35–3.92)</td>
<td>0.789</td>
</tr>
<tr>
<td>NEC</td>
<td>4 (2.1)</td>
<td>3 (1.6)</td>
<td>1.33 (0.30–5.85)</td>
<td>0.708</td>
<td>1.41 (0.34–5.80)</td>
<td>0.634</td>
</tr>
<tr>
<td>IVH Grade III/IV</td>
<td>0</td>
<td>1 (0.5)</td>
<td>0.33 (0.01–8.09)†</td>
<td>0.316</td>
<td>0.39 (0.02–8.93)†</td>
<td>0.355</td>
</tr>
<tr>
<td>PVL</td>
<td>0</td>
<td>0</td>
<td>Not estimable</td>
<td>NA</td>
<td>Not estimable</td>
<td>NA</td>
</tr>
<tr>
<td>Perinatal death</td>
<td>3 (1.6)</td>
<td>6 (3.1)</td>
<td>0.50 (0.13–1.96)</td>
<td>0.309</td>
<td>0.43 (0.10–1.90)</td>
<td>0.248</td>
</tr>
<tr>
<td>Neonatal death</td>
<td>2 (1.0)</td>
<td>3 (1.6)</td>
<td>0.66 (0.11–3.93)</td>
<td>0.649</td>
<td>0.70 (0.12–4.18)</td>
<td>0.697</td>
</tr>
<tr>
<td>Any morbidity/mortality event</td>
<td>11 (5.7)</td>
<td>21 (10.9)</td>
<td>0.52 (0.26–1.05)</td>
<td>0.063</td>
<td>0.50 (0.24–1.03)</td>
<td>0.053</td>
</tr>
<tr>
<td>Birth weight &lt; 2500 g</td>
<td>45 (23.2)</td>
<td>54/192 (28.1)</td>
<td>0.82 (0.59–1.16)</td>
<td>0.268</td>
<td>0.80 (0.57–1.13)</td>
<td>0.210</td>
</tr>
<tr>
<td>Birth weight &lt; 1500 g</td>
<td>8 (4.1)</td>
<td>22/192 (11.5)</td>
<td>0.36 (0.16–0.79)</td>
<td>0.007</td>
<td>0.37 (0.17–0.80)</td>
<td>0.008</td>
</tr>
</tbody>
</table>

*Unadjusted relative risk (RR) and 95% CI calculated using the Cochran–Mantel–Haenszel (CMH) method; P-value based on CMH test.
†RR and 95% CI calculated using the CMH method adjusted for pooled study site and risk strata; P-value based on CMH test adjusted for pooled study site and risk strata. ‡Based on Logit estimator with continuity correction. BPD, bronchopulmonary dysplasia; GA, gestational age; IVH, intraventricular hemorrhage; NA, not applicable; NEC, necrotizing enterocolitis; PVL, periventricular leukomalacia; RDS, respiratory distress syndrome.

To reduce preterm birth is improvement in infant outcome. To date, no intervention in an asymptomatic patient with a risk factor has demonstrated both a reduction in preterm birth and an improvement in infant outcome, without a safety signal44. The results of this trial indicate that a combined approach, in which transvaginal sonographic cervical length is used to identify patients at risk for preterm delivery, followed by the administration of vaginal progesterone gel from the mid-trimester of pregnancy until term, reduces the rate of both preterm birth before 33 weeks of gestation and RDS, the most common complication of preterm neonates. In addition to the primary and secondary endpoints related to gestational age, administration of vaginal progesterone

gel was associated with a significant reduction in the proportion of infants with any morbidity/mortality event, and a significant improvement in neonatal outcome was demonstrated through two additional composite scores as well as a significant reduction in birth weight < 1500 g. Of note, vaginal progesterone gel was well-tolerated and compliance was substantial (> 90%).

Results in the context of other studies

The primary result of this trial is similar to that reported by Fonseca et al.27, who found that vaginal progesterone (200 mg vaginal capsules) administered to women with a cervical length ≤ 15 mm at a median gestational age of 23 weeks reduced the rate of spontaneous preterm (< 34 weeks) delivery by 44%. In our trial, there was a 45% reduction in the rate of preterm delivery before 33 weeks. This finding is robust because it was supported by a significant 38% reduction in the rate of preterm birth < 35 weeks, a 50% reduction at < 28 weeks, and a 53% reduction in the rate of birth weight < 1500 g. In addition, the reduction in preterm birth observed in this trial translated into the improvement of clinically important neonatal outcomes such as RDS and three composite perinatal mortality/neonatal morbidity scores.

Both the study by Fonseca et al.27 and the current trial used a similar approach to identify the patients at risk, namely, screening with transvaginal sonography to diagnose a short cervix. Differences between the trials are that: 1) our study excluded twin gestations, which have not been shown to benefit from the prophylactic administration of progesterone49 or 17 alpha-hydroxyprogesterone caproate46; 2) the cervical length for entry into our study was 10–20 mm. Patients with a cervical length of 10 mm or less have a higher rate of intra-amniotic infection/inflammation48 and are less likely to benefit from progesterone administration than are patients with a longer cervix. We extended the upper limit of cervical length to 20 mm to explore whether vaginal progesterone gel would have a beneficial effect beyond 15 mm and therefore expand its therapeutic range; 3) the treatment protocol in our study called for initiation of vaginal progesterone as early as 20 weeks of gestation, continuing until 36 + 6 weeks, while Fonseca et al.27 began at 24 weeks and stopped at 34 weeks (it is possible that earlier treatment may confer more beneficial effects); and 4) the formulation of vaginal progesterone was different. Fonseca et al.27 used oil capsules containing 200 mg progesterone, while we employed a bioadhesive gel with 90 mg progesterone. The vaginal gel preparation has been shown to be biologically active in supporting pregnancies in the first trimester undergoing assisted reproductive technology and, despite the lower dose of progesterone, our current trial results indicate that the dose was sufficient to reduce the rate of preterm delivery. We postulate that this is attributable to the bioadhesive nature of the preparation, which may enhance bioavailability.

Strengths and limitations of the study

The strengths of this study are that it was a multicenter, placebo-controlled, double-masked, randomized trial with rigorous standards for the allocation of treatment and concealment of the identity of the treatment. The placebo and vaginal progesterone gel preparations were identical in appearance and procedures were in place to reduce the risk of other biases. We also performed an additional sensitivity analysis in the ITT analysis set to provide a ‘worst-case’ scenario, in which women lost to follow-up who received vaginal progesterone were considered as if they had a preterm birth before 33 weeks of gestation whereas women lost to follow-up who received placebo were considered as if they had a term delivery (≥ 37 weeks of gestation). Even in this worst-case scenario of the ITT analysis set, the beneficial effect of vaginal progesterone on the rate of preterm birth before 33 weeks of gestation remained significant (9.3% (22/236) vs 15.7% (36/229); RR = 0.59; 95% CI, 0.36–0.98; P = 0.04).

Another strength of this study is its apparent external validity, supported by the following: 1) our primary results were consistent with those of a similar trial27 that tested the effects of vaginal progesterone capsules in women with a short cervix and reported a similar effect size; 2) the preterm delivery rate in the placebo arm was similar to that reported in studies in the literature12,17,49; 3) there was no treatment by site interaction albeit with the necessity to pool sites for this test; and 4) the multinational nature of the trial, in which there was substantial representation (approximately 30%) for each of the following ethnic groups: African-American, Asian and Caucasian.

A limitation of the study is that the primary endpoint is a surrogate for infant outcome. The use of surrogate endpoints is common in clinical trials because of the pragmatic challenges in the execution of trials when infant outcome is the primary outcome of interest. Our study was not powered to detect differences in the outcome according to risk strata (presence or absence of a previous preterm birth).

Sonographic cervical length to identify the patient at risk for preterm delivery

It is now well-established that the shorter the sonographic cervical length in the mid-trimester, the higher the risk of preterm delivery12,14–23,25. Indeed, it is possible to assign an individualized risk50 for preterm delivery using sonographic cervical length and other maternal risk factors, such as maternal age, ethnic group, BMI and previous cervical surgery. Among these factors, sonographic cervical length is the most powerful predictor for preterm birth in the index pregnancy, and is more informative than is a history of previous preterm birth14,17. Selecting patients for prophylactic administration of progestogens based only on a history of a previous preterm birth36,51–53 would have an effect.

Vaginal progesterone reduces preterm birth in women with a short cervix

(although limited) on the prevention of preterm delivery worldwide, because most women who deliver preterm neonates do not have this history. Moreover, such strategy cannot be implemented in nulliparous women; therefore, universal risk assessment (primigravidae and parous women) is possible with transvaginal cervical ultrasound. A pharmacoeconomic study is in progress to address the issue of cost-effectiveness, based on the observations of this study.

The effect of progesterone on the uterine cervix

Although the original focus of the effect of progesterone in pregnancy maintenance was on the myometrium, it is now clear that this hormone exerts biological effects on the chorioamniotic membranes and the uterine cervix. Indeed, progesterone is considered key in the control of cervical ripening. The precise mechanism by which progesterone prevents preterm delivery in women with a short cervix has not been established. A local effect is likely, given the high concentrations of circulating progesterone in pregnant women.

Differences among progestogens

The term ‘progestogen’, like ‘progestin’, includes both natural progesterone and synthetic compounds with progesterone-like actions. The compound used in this study is identical to natural progesterone, as was the case in the study by Fonseca et al. Progesterone is currently approved to support pregnancies in the first trimester in patients undergoing assisted reproductive technologies in the United States, Europe and other countries. The safety profile of the preparation used in this study is well-established. In contrast, there are no data to date to support the use of 17-alpha hydroxyprogesterone caproate, a synthetic progestogen, to prevent preterm birth in women with a sonographic short cervix.

Future studies

Additional studies are necessary to determine if treatment of women with a short cervix in the early second trimester may further reduce the rate of preterm delivery. Moreover, it is important to determine if women with twin gestations who have a short cervix may also benefit from vaginal progesterone. The previous negative results of a randomized clinical trial in twin gestations could be attributed to the inclusion of patients with a long cervix who thus may not have benefited from vaginal progesterone. The optimal treatment of patients with a cervical length < 10 mm remains a challenge. Similarly, whether vaginal progesterone may modify the effect of vaginal cerclage remains to be determined.

Importance of the findings

The potential impact of this intervention in clinical practice can be surmised from the estimate that 14 patients need to be treated to prevent one preterm birth before 33 weeks of gestation. Moreover, 22 patients need to be treated to prevent one episode of RDS. These figures compare well with those of two interventions used widely in obstetrics: 100 patients with pre-eclampsia need to be treated with magnesium sulfate to prevent one case of eclampsia and 13 women at high risk of preterm birth need to receive antenatal corticosteroids to prevent one case of RDS.

Implications for clinical practice

The main implication of this study for clinical practice is that universal screening of women with transvaginal sonography to measure cervical length in the mid-trimester to identify patients at risk can now be coupled with an intervention – the administration of vaginal progesterone gel – to reduce the frequency of preterm birth and improve neonatal outcome.

ACKNOWLEDGMENTS

This clinical trial was conducted pursuant to a Clinical Trials Agreement between the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) of the National Institutes of Health (NIH), Department of Health and Human Services (DHHS) of the United States, and Columbia Laboratories, Inc., Livingston, New Jersey, USA. We would like to thank the patients who participated in this trial, as well as the coordinators, physicians, nurses, sonographers and administrative staff who assisted in the execution of this study.

Contributors

S.S.H., R.R., D.V., S.F., J.K.B., M.K., J.V., Y.T., P.S.P., P.S., A.D., V.P., J.O., V.A., O.Y., W.K., B.D., H.S., L.M., D.M., M.T.G. and G.W.C. contributed to the conception, design, management and interpretation of data, drafting and critically revising the manuscript for important intellectual content, and approving the final version to be published. J.A.P., L.S. and A.C.A. contributed to data analysis and interpretation, as well as drafting and critically revising the manuscript for important intellectual content, and approving the final version to be published. L.S. and A.C.A. were funded exclusively by NICHD/NIH and not Columbia Laboratories, Inc.

Investigators participating in the study

The PREGNANT Trial investigators included: L. Mazheika, S. Zanko (Belarus, Republic of); J. Ortiz Castro, E. Oyarzun (Chile); P. Calda (Czech Republic); S. Fusey, P. Sambarey, Y. Trivedi, D. Vidyadhari, J. Vijayaraghavan (India); A. Bashiri, Y. Hazan, I. Hendler (Israel); M.T. Gervasi (Italy); A. Mikhailov (Russia); P. Soma-Pillay (South Africa); V. Astakhov, D. Manchulenko, V. Potapov, A. Schenck, O. Yuzko (Ukraine);
Role of the funding source

The study was funded in part by the Intramural Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development/National Institutes of Health and Columbia Laboratories, Inc.

The authors were responsible for the study design, data collection and interpretation of the results of the data analysis. The Perinatology Research Branch of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)/National Institutes of Health (NIH) was responsible for the writing of the report and the decision to submit the paper for publication. The funding sources (NICHD/NIH and Columbia Laboratories, Inc.) were not involved in writing the report or the decision to submit the paper for publication.

CONFLICTS OF INTEREST

S.H., R.R., M.T.G., A.C.A., W.K. and L.S. have no financial interest. Author-investigators D.V., S.F., J.B., M.K., J.V., Y.T., P.S.-P., P.S., A.D., J.O.B., V.A., O.Y., B.D., H.S., L.M. and D.M. conducted this study with the support of grants awarded by Columbia Laboratories, Inc. for the specific purpose of conducting this trial. The terms and conditions for the awarding of the grants were consistent with those which are customary for this type of industry-sponsored trial and all payments were independent of the outcome of the trial. In addition, J.K.B. and J.O.B. have also received consulting fees and travel expenses related to Preterm Birth Advisory Committee meetings related to the project. J.O.B. is an inventor on a patent for the use of progesterone in the prevention of preterm birth. J.A.P. received remuneration as a statistical consultant to Columbia Laboratories, Inc. G.W.C. is an employee of Columbia Laboratories, Inc.

REFERENCES

Vaginal progesterone reduces preterm birth in women with a short cervix


32. Alfirevic Z. Cerclage: we all know how to do it but can’t agree when to do it. Obstet Gynecol 2006; 107 (2 Pt 1): 219–220.


Vaginal progesterone reduces preterm birth in women with a short cervix

31

93. Xu H, Gonzalez JM, Ofori E, Elovitz MA. Preventing cervical
92. Elovitz MA, Gonzalez J. Medroxyprogesterone acetate modu-
91. Andersson S, Minjarez D, Yost NP, Word RA. Estrogen and
90. Word RA, Li XH, Hnat M, Carrick K. Dynamics of cervical
89. Marx SG, Wentz MJ, Mackay LB, Schlembach D, Maul H,
88. Tornblom SA, Patel FA, Bystrom B, Giannoulias D, Malm-
85. Bennett P, Allport V, Loudon J, Elliott C. Prostaglandins, the
84. Carbonne B, Dallot E, Haddad B, Ferré F, Cabrol D. Effects of

SUPPORTING INFORMATION ON THE INTERNET

The following supporting information, provided by the authors, may be found in the online version of this article:

Appendix S1 Definitions of neonatal morbidity/mortality and definitions of composite perinatal mortality/neonatal morbidity outcome scores.

Appendix S2 Definition of adverse events.

Appendix S3 Trial profile.

Appendix S4 Frequency distributions for perinatal mortality/neonatal morbidity composite scores: intention-to-treat analysis set.
Supplementary Material

Appendix S1 Definitions of Neonatal Morbidity/Mortality*1,2

Intraventricular Hemorrhage3,4 (as determined by cranial ultrasound or CT)
Grade I – subependymal hemorrhage
Grade II – intraventricular hemorrhage, uncomplicated
Grade III – intraventricular hemorrhage with ventricular dilatation
Grade IV – intraventricular hemorrhage with ventricular dilatation and parenchymal extension

Necrotizing Enterocolitis5
Surgical – Stage III – Advanced
- Treatment was surgical

Other findings may include:
- perinatal stress
- systemic manifestations such as temperature instability, lethargy, apnea, bradycardia, occult or gross GI bleeding, abdominal distension, plus septic shock
- radiographs show: intestinal distension with ileus, small bowel separation, rigid bowel loops, pneumatosis intestinalis, portal vein gas, pneumoperitoneum

*The definitions provided (except bronchopulmonary dysplasia) are those described in the manual of operations of the Maternal-Fetal Medicine Units Network for randomized clinical trials designed to prevent prematurity with 17-alpha hydroxyprogesterone caproate
Clinical – Stage II – Definite

- Treatment was medical

Other findings may include:

- perinatal stress
- systemic manifestations such as temperature instability, lethargy, apnea, bradycardia, occult or gross GI bleeding, abdominal distension
- radiographs show: intestinal distension with ileus, small bowel separation, rigid bowel loops, pneumatosis intestinalis, portal vein gas

Other – Stage I – Suspect

- Treatment was observation

Other findings may include:

- perinatal stress
- systemic manifestations such as temperature instability, lethargy, apnea, bradycardia
- radiographs show: intestinal distension with ileus

Respiratory Distress Syndrome (both diagnosis and oxygen therapy)

- Clinical Diagnosis of at least RDS type I (one or more of the following):
  - tachypnoea (respiratory rate > 60 breaths per minute)
  - intercostal, subcostal, and sternal recession
  - expiratory grunting
  - cyanosis
  - diminished breath sounds
- oxygen therapy \( (\text{FiO}_2 \geq 0.40) \) until infant death or \( \geq 24 \) hours

Retinopathy

- Stage I (ophthalmoscopic demarcation line of normal and abnormal vessels)
- Stage II (intraretinal ridge (ridge that rises up from the retina as a result of the growth of the abnormal vessels))
- Stage III (ridge with extraretinal fibrovascular proliferation (the ridge grows from the spread of the abnormal vessels and extends into the vitreous))

Bronchopulmonary Dysplasia

- Treatment with > 21% O\(_2\) for at least 28 days, or
- O\(_2\) dependence after 36 weeks post-conceptional age

Proven Sepsis

- Clinically ill infant with suspected infection plus
- Positive blood, CSF, or catheterized/suprapubic urine culture or cardiovascular collapse or unequivocal X-ray finding

Definitions of Composite Perinatal Mortality/Neonatal Morbidity Outcome Scores:

1) 0 to 4 scale without NICU: This score was derived as an ordinal scale based upon severity. The score was defined by the following: 0=no events; 1=one event for (RDS, BPD, grade III or IV IVH, PVL, proven sepsis, or NEC) and no perinatal mortality, 2=two events and no perinatal mortality; 3=three or more events and no perinatal mortality; and 4=perinatal mortality.
2) 0 to 4 scale with NICU: This score was defined as the following: 0=no events, 1=one event for (RDS, BPD, grade III or IV IVH, PVL, proven sepsis, or NEC) or <5 days in the NICU, and no perinatal mortality; 2=two events or between 5 and 20 days in the NICU, and no perinatal mortality; 3=three or more events or >20 days in the NICU, and no perinatal mortality; and 4=perinatal mortality.

3) 0 to 6 scale without NICU: This score was defined as the following: 0=no events; 1=one event for (RDS, BPD, grade III or IV IVH, proven sepsis, or NEC) and no perinatal mortality, 2=two events and no perinatal mortality; 3=three events and no perinatal mortality; 4=four events and no perinatal mortality; 5=five events and no perinatal mortality; and 6=perinatal mortality.

4) Any morbidity or mortality event: (yes/no)

**Appendix S2** Definition of Adverse Events

The Medical Dictionary for Regulatory Activities (MedDRA) dictionary (version 11.0) was used to classify all adverse events reported during the study by system organ class and preferred term. The incidence of treatment-emergent adverse events (TEAEs) was also determined. TEAEs were defined as those adverse events that either had an onset time on or after the start of study drug and no more than 30 days after the last dose of study drug, or were ongoing at the time of study drug initiation and increased in severity, or became closer in relationship to study drug during the treatment period.

**Appendix S3** Trial Profile

This section describes patients lost to follow-up and protocol violations.
Patients lost to follow-up: There were seven patients lost to follow-up in which the investigators were not able to obtain delivery date. Six patients had been allocated to the placebo group and one to the progesterone group.

Protocol violations: This will be itemized by category:

a) One patient had a cervical length of 21 mm when the upper limit of cervical length for enrollment was 20 mm. This patient was randomised to receive progesterone.

b) One patient was enrolled despite having had a prophylactic cerclage. The protocol required that patients with a cerclage be excluded from participation. This patient was allocated to the placebo group.

c) One patient had a positive test for HIV. The protocol specified that patients testing positive for HIV should be excluded. She was allocated to receive progesterone.

d) Two patients were prescribed progesterone administration. The protocol specified that patients should not have progesterone administration. These two patients were allocated to progesterone administration in the trial.

e) A total of 55 patients began study drug before or after the planned interval of 20 – 23 6/7 weeks, as specified in the protocol, based on the date of the first dose of study drug and the accepted estimated date of confinement. The specific detail for these patients is the following:

   i. 20 patients allocated to placebo began therapy before 20 weeks; range 17-19 6/7 weeks

   ii. 9 patients allocated to progesterone began therapy before 20 weeks; range 19 – 19 6/7 weeks
iii. 7 patients allocated to placebo began therapy after 23 6/7 weeks; range 24 – 25 weeks

iv. 19 patients allocated to progesterone began therapy after 23 6/7 weeks; range 24 – 25 3/7 weeks

An additional analysis was conducted in which the following patients were removed: (those who started placebo or progesterone before or after the gestational age prescribed in the protocol, those who had a cerclage or those with a history of cervical surgery). This analysis demonstrated a 49% reduction in the rate of preterm birth before 33 weeks of gestation in women who were randomly allocated to receive vaginal progesterone (7.9% (15/189) vs 15.7% (27/172); RR, 0.51; 95%CI, 0.28-0.92; p=0.022). The reduction of preterm birth at <28 weeks of gestation was also statistically significant (4.2% vs 11.1%; RR, 0.38; 95% CI, 0.17-0.85; p=0.014 in this subpopulation. Similarly, the reduction at <35 weeks was also statistically significant (13.2% vs 23.3%; RR, 0.57; 95%CI, 0.36-0.90; p=0.013).

**Appendix S4** Frequency Distributions for Perinatal Mortality/Neonatal Morbidity Composite Scores – ITT analysis set

<table>
<thead>
<tr>
<th>Score</th>
<th>Placebo n</th>
<th>Prochieve n</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>192</td>
<td>217</td>
</tr>
<tr>
<td>1</td>
<td>11</td>
<td>5</td>
</tr>
<tr>
<td>2</td>
<td>8</td>
<td>2</td>
</tr>
<tr>
<td>3</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>4</td>
<td>11</td>
<td>8</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Score</th>
<th>Placebo n</th>
<th>Prochieve n</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>168</td>
<td>194</td>
</tr>
<tr>
<td>1</td>
<td>11</td>
<td>6</td>
</tr>
<tr>
<td>2</td>
<td>17</td>
<td>19</td>
</tr>
<tr>
<td>3</td>
<td>15</td>
<td>8</td>
</tr>
<tr>
<td>4</td>
<td>11</td>
<td>8</td>
</tr>
</tbody>
</table>
### 0 – 6 scale

<table>
<thead>
<tr>
<th>Score</th>
<th>Placebo(n)</th>
<th>Prochieve(n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>192</td>
<td>217</td>
</tr>
<tr>
<td>1</td>
<td>11</td>
<td>5</td>
</tr>
<tr>
<td>2</td>
<td>8</td>
<td>2</td>
</tr>
<tr>
<td>3</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>4</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>5</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>6</td>
<td>11</td>
<td>8</td>
</tr>
</tbody>
</table>
References


